NSE Symbol

KRSNAA

Krsnaa Diagnostics Limited submitted an investor presentation to the BSE and NSE pursuant to Regulation 30 of SEBI LODR Regulations, covering its unaudited financial results for the quarter ended June 30, 2026 (Q1 FY27).

Financial Performance (Consolidated, INR million)

Revenue: Q1 FY27 revenue was ₹2,355 million, compared to ₹1,930 million in Q1 FY26 (22% growth) and ₹1,926 million in Q4 FY26.

EBITDA: EBITDA before CSR & ESOP was ₹588 million in Q1 FY27 (25% margin), compared to ₹524 million (27% margin) in Q1 FY26 and ₹559 million (29% margin) in Q4 FY26. After accounting for CSR & ESOP expenses of ₹8 million, reported EBITDA was ₹580 million.

PAT: Profit After Tax was ₹166 million in Q1 FY27 (7% margin), a decrease from ₹205 million (11% margin) in Q1 FY26 and ₹416 million (22% margin) in Q4 FY26.

Expense Breakdown: Cost of materials consumed was ₹502 million (21% of revenue); Employee benefits expense was ₹357 million (15%); Fees to hospitals and others was ₹406 million (17%); Other expenses were ₹502 million (21%).

Other Items: Finance costs were ₹148 million (6% of revenue); Depreciation was ₹280 million (12%); Other income was ₹72 million (3%); Tax expense was ₹59 million (2%).

The company attributed the moderation in margins primarily to the upfront fixed cost base of Rajasthan laboratories, equipment, manpower, and logistics being carried ahead of full utilization.

Operational Metrics

Tests Performed: 16.1 million tests in Q1 FY27, a 2% increase from 15.8 million in Q1 FY26.

Patients Served: 5.1 million patients in Q1 FY27, a 2% increase from 5.0 million in Q1 FY26.

Accreditations: The company maintained 54 NABL-accredited pathology labs and significantly expanded its NABH-accredited radiology centers to 66, a 113% increase from 31 in Q1 FY26.

Business Strategy and Growth Drivers

The presentation outlines a retail-focused growth strategy built on a partnership (PPP) model. Key pillars include:

  • Scale & Modality Advantage: Leveraging existing PPP infrastructure for retail services with minimal incremental fixed cost.
  • Asset-Light Franchise Model: Partnerships with local operators for rapid expansion.
  • Hub-and-Spoke Architecture: Centralized reference labs processing samples from a satellite network.
  • Home Collection Scale-Up: Expanding phlebotomist network and digital platform.
  • Awareness: Aggregator and platform partnerships, corporate wellness programs, and a 30,000+ doctor network.
  • Technology: AI-powered radiology, digital pathology, and a teleradiology platform.

The company highlighted its pricing strategy, offering services at over 70% below market rates for key tests like MRI Brain (₹1,340 vs. competitor range of ₹7,000-8,250) and Pathology Vitamin B12 (₹69 vs. competitor range of ₹1,000-1,300).

Forward-Looking Statements & Disclaimer

The presentation contains forward-looking statements related to strategic initiatives and future performance, qualified by risks including market conditions, regulatory trends, currency exchange rates, competitive pressures, and technological developments. The company undertakes no obligation to revise these statements.